Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 7/20 | 0.45 |
| ▸ | SHMT2 | P34897 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | EIF4E | P06730 | 2/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869889 | 1.00 | SHMT1 (0.45) | SHMT1SHMT2CNR2LMNATP53 | |
| SCHEMBL5869890 | 1.00 | SHMT1 (0.45) | SHMT1SHMT2CNR2LMNATP53 | |
| SCHEMBL6834297 | 0.95 | SHMT1 (0.43) | SHMT1SHMT2CNR2LMNATP53 | |
| SCHEMBL7424643 | 0.87 | CTSK (0.39) | SHMT1SHMT2CNR2LMNATP53 | |
| SCHEMBL7424634 | 0.86 | TP53 (0.38) | SHMT1SHMT2CNR2LMNATP53 | |
| SCHEMBL5869959 | 0.86 | ACE2 (0.48) | SHMT1SHMT2GRNSORT1ACE2 | |
| SCHEMBL5869952 | 0.86 | ACE2 (0.48) | SHMT1SHMT2GRNSORT1ACE2 | |
| SCHEMBL6927461 | 0.86 | ACE2 (0.48) | SHMT1SHMT2GRNSORT1ACE2 | |
| SCHEMBL5869503 | 0.86 | ACE2 (0.48) | SHMT1SHMT2GRNSORT1ACE2 | |
| SCHEMBL5869868 | 0.84 | SHMT1 (0.60) | SHMT1SHMT2SMN1; SMN2KDM4EGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | SHMT1 1885/4885SHMT2 1220/4885CNR2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.